Market Place
Sourcing Support
Altimmune Presents Pemvidutide Data in MASLD at The Liver Meeting®
15 Nov 2024 //
GLOBENEWSWIRE
Altimmune Announces Q3 2024 Financial Results & a Business Update
12 Nov 2024 //
GLOBENEWSWIRE
Altimmune Appoints Life Industry Veteran Greg Weaver as CFO
11 Nov 2024 //
GLOBENEWSWIRE
Altimmune Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
11 Nov 2024 //
GLOBENEWSWIRE
Altimmune Completes End-of-Phase 2 Meeting with FDA for Pemvidutide
07 Nov 2024 //
GLOBENEWSWIRE
Altimmune to Participate at Two Upcoming Investor Conferences
06 Nov 2024 //
GLOBENEWSWIRE
Altimmune to Report Q3 2024 Results and Business Update Nov 12
04 Nov 2024 //
GLOBENEWSWIRE
Altimmune To Present New Data On Lipidomic Profile With Pemvidutide
15 Oct 2024 //
GLOBENEWSWIRE
Altimmune Joins H.C. Wainwright 8th Annual MASH Virtual Conference
01 Oct 2024 //
GLOBENEWSWIRE
Altimmune Completes Enrollment In IMPACT Trial For Pemvidutide
30 Sep 2024 //
GLOBENEWSWIRE
Altimmune Presents Phase 2 Body Composition Study Results
10 Sep 2024 //
GLOBENEWSWIRE
Altimmune Presents Phase 2 MRI Body Composition Results
10 Sep 2024 //
GLOBENEWSWIRE
Altimmune to Present Pemvidutide Data at European Diabetes Meeting
03 Sep 2024 //
GLOBENEWSWIRE
Altimmune Announces Q2 2024 Results And Provides Business Update
08 Aug 2024 //
GLOBENEWSWIRE
Altimmune To Report Q2 2024 Results On August 8
01 Aug 2024 //
GLOBENEWSWIRE
Altimmune Publishes Pemvidutide MASLD Study In Hepatology Journal
25 Jul 2024 //
GLOBENEWSWIRE
Altimmune to Participate at Leerink Partners Therapeutics Forum
02 Jul 2024 //
GLOBENEWSWIRE
Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt
26 Jun 2024 //
GLOBENEWSWIRE
Altimmune touts `best-in-class` lean mass results for weight loss therapy
23 Jun 2024 //
FIERCE BIOTECH
Altimmune To Participate In Piper Sandler 2nd Annual Virtual Obesity Day
20 Jun 2024 //
GLOBENEWSWIRE
Altimmune: EASL 2024 Data Supports Pemvidutide In MASH
05 Jun 2024 //
GLOBENEWSWIRE
Anti-Obesity Drugs Market Report On Major Pharma Players
31 May 2024 //
BUSINESSWIRE
Altimmune`s Pemvidutide Data At EASL Liver Congress 2024
29 May 2024 //
GLOBENEWSWIRE
Altimmune to Participate at Two Upcoming Investor Conferences
29 May 2024 //
GLOBENEWSWIRE
Altimmune Q1 2024 Financials And Business Update
09 May 2024 //
GLOBENEWSWIRE
Altimmune to Participate at Two Upcoming Investor Conferences
07 May 2024 //
GLOBENEWSWIRE
Altimmune Q1 2024 Results, Business Update On May 9
02 May 2024 //
GLOBENEWSWIRE
Altimmune to Participate at Two Upcoming Conferences
01 May 2024 //
GLOBENEWSWIRE
Altimmune Statement on the Passing of Dr. Stephen Harrison
25 Apr 2024 //
GLOBENEWSWIRE
Altimmune Announces Positive Data for Pemvidutide and Financial Results
27 Mar 2024 //
GLOBENEWSWIRE
Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results
20 Mar 2024 //
GLOBENEWSWIRE
Altimmune: Taking On Toughest Of Rivals In Obesity - I`m Unconvinced By Rally
27 Feb 2024 //
SEEKING ALPHA
Altimmune Announces Presentation of Pemvidutide Clinical Data
02 Jan 2024 //
GLOBENEWSWIRE
Altimmune’s pemvidutide meets weight-loss expectations in study
01 Dec 2023 //
GLOBENEWSWIRE
Altimmune Announces Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Altimmune to Report Third Quarter 2023 Financial Results
31 Oct 2023 //
GLOBENEWSWIRE
Altimmune Granted Fast Track Designation by FDA for Pemvidutide
26 Oct 2023 //
GLOBENEWSWIRE
Altimmune to Present New Data on the Anti-Inflammatory Properties of Pemvidutide
25 Oct 2023 //
GLOBENEWSWIRE
Altimmune to Participate at Two Upcoming Investor Conferences
17 Oct 2023 //
GLOBENEWSWIRE
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data
26 Sep 2023 //
GLOBENEWSWIRE
Altimmune Announces Completion of Dosing in the Phase 2 Trial of Pemvidutide
12 Sep 2023 //
GLOBENEWSWIRE
Altimmune to Participate at Two Upcoming Investor Conferences
30 Aug 2023 //
GLOBENEWSWIRE
Altimmune Announces Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Altimmune to Report Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating Pemvidutide
01 Aug 2023 //
GLOBENEWSWIRE
Altimmune to Participate in the Healthcare Conference Presented by Maxim
16 Jun 2023 //
GLOBENEWSWIRE
Altimmune Announces Oral Presentation of Pemvidutide Data in Treatment of NAFLD
15 Jun 2023 //
GLOBENEWSWIRE
Altimmune to Participate at Two Upcoming Investor Conferences
31 May 2023 //
GLOBENEWSWIRE
Altimmune Announces First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Altimmune to Participate at Two Upcoming Investor Conferences
08 May 2023 //
GLOBENEWSWIRE
Altimmune to Report 1Q 2023 FYR and Provide Business Update on May 11, 2023
04 May 2023 //
GLOBENEWSWIRE
Novo Nordisk rivals see room to compete in $100 billion weight-loss drug market
04 May 2023 //
REUTERS
Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell
11 Apr 2023 //
GLOBENEWSWIRE
Altimmune Appoints Former Catherine Angell Sohn to Board of Directors
27 Mar 2023 //
GLOBENEWSWIRE
Altimmune`s obesity drug safety concerns shrink shares
21 Mar 2023 //
REUTERS
Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results
28 Feb 2023 //
GLOBENEWSWIRE
Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results
21 Feb 2023 //
GLOBENEWSWIRE
Coronavirus (COVID-19) Current Therapy Global Market Report 2023
14 Feb 2023 //
PR NEWSWIRE
